From: Prognostic impact of ICG-PDR in patients with hypoxic hepatitis
Patients with liver disease | HH | ALF | Cirrhosis | Control | |
---|---|---|---|---|---|
Parameter | |||||
n | 97 | 52 | 10 | 35 | 22 |
Male, (%) | 61 (63) | 34 (65) | 4 (40) | 23 (66) | 16 (73) |
Age, yearsa, b, e | 54 (44–66) | 64 (47–76) | 40 (35–49) | 48 (39–57) | 53 (44–67) |
SOFAb, c | 12 (8–16) | 13 (9–16.8) | 9 (5.8–14) | 11 (7–14) | 10.5 (7–13) |
SAPS IIa, b, c | 57 (38–71) | 60.5 (43.3–78.5) | 26.5 (15.8–56.5) | 51 (35–67) | 50 (36–59) |
MELDa, c, d, e, f | 22 (17–30) | 21.5 (15–28.8) | 31 (24.5–35.3) | 19 (17–30) | 8 (6–14.5) |
Mechanical ventilation, (%)e, f | 75 (77) | 42 (81) | 7 (70) | 26 (74) | 21 (96) |
Vasopressor, (%)a | 74 (76) | 45 (87) | 4 (50) | 24 (69) | 17 (77) |
Mean arterial pressure, mmHg | 72 (65.5–83.5) | 71.5 (68.3–77) | 75.5 (66.8–88.3) | 70 (65–80) | 72 (65.5–83.5) |
Heart rate, beat/min | 94 (80–111.5) | 95 (83–113.8) | 93.5 (83.3–105) | 92 (80–113) | 90 (76.8–105) |
Renal replacement therapy, (%) | 39 (40) | 21 (40) | 6 (60) | 12 (34) | 5 (23) |
28-day mortality, (%)a, d | 48 (49) | 27 (52) | 1 (10) | 20 (57) | 7 (32) |